BACKGROUND: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TNF and subsequently induces apoptosis of activated lamina propria T lymphocytes in patients with Crohn's disease in vitro. AIM: To test whether the ability of rapid anti-TNF-induced apoptosis in the gut predicts the efficacy of anti-TNF treatment in inflammatory bowel disease. METHODS: (99m)Technetium-annexin V single-photon emission computer tomography (SPECT) was performed in 2 models of murine experimental colitis and in 14 patients with active Crohn's disease as assessed by the Crohńs Disease Activity Index (CDAI) to study the effect of anti-TNF treatment on apoptosis in the intestine during active colitis. Disease activity was evaluated 2 weeks after infliximab infusion using the CDAI (definition response: drop of >100 points). RESULTS: Colonic uptake of (99m)Tc-annexin V significantly increased in 2,4,6-trinitrobenzene sulphonate-induced colitis as well as in transfer colitis on administration of anti-TNF antibodies compared with a control antibody as determined with dedicated animal pinhole SPECT. In addition, uptake of (99m)Tc-annexin V significantly increased in patients with active Crohn's disease responding to infliximab treatment. Colonic (99m)Tc-annexin V uptake ratio (mean (SEM)) increased from 0.24 (0.03) to 0.41(0.07) (p<0.01), 24 h after infliximab infusion (5 mg/kg). A mean increase of 98.7% in colonic uptake of (99m)Tc-annexin V could be detected in 10 of the 14 responding patients (CDAI >100 points at week 2) compared with 15.2% in non-responding patients (p = 0.03). Analysis of the mucosal biopsy specimens identified lamina propria T cells as target cells undergoing apoptosis. CONCLUSIONS: These in vivo observations support the notion that colonic uptake of (99m)Tc-annexin V correlates with clinical benefit of anti-TNF treatment and might be predictive of therapeutic success.
BACKGROUND: The humananti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TNF and subsequently induces apoptosis of activated lamina propria T lymphocytes in patients with Crohn's disease in vitro. AIM: To test whether the ability of rapid anti-TNF-induced apoptosis in the gut predicts the efficacy of anti-TNF treatment in inflammatory bowel disease. METHODS: (99m)Technetium-annexin V single-photon emission computer tomography (SPECT) was performed in 2 models of murine experimental colitis and in 14 patients with active Crohn's disease as assessed by the Crohńs Disease Activity Index (CDAI) to study the effect of anti-TNF treatment on apoptosis in the intestine during active colitis. Disease activity was evaluated 2 weeks after infliximab infusion using the CDAI (definition response: drop of >100 points). RESULTS: Colonic uptake of (99m)Tc-annexin V significantly increased in 2,4,6-trinitrobenzene sulphonate-induced colitis as well as in transfer colitis on administration of anti-TNF antibodies compared with a control antibody as determined with dedicated animal pinhole SPECT. In addition, uptake of (99m)Tc-annexin V significantly increased in patients with active Crohn's disease responding to infliximab treatment. Colonic (99m)Tc-annexin V uptake ratio (mean (SEM)) increased from 0.24 (0.03) to 0.41(0.07) (p<0.01), 24 h after infliximab infusion (5 mg/kg). A mean increase of 98.7% in colonic uptake of (99m)Tc-annexin V could be detected in 10 of the 14 responding patients (CDAI >100 points at week 2) compared with 15.2% in non-responding patients (p = 0.03). Analysis of the mucosal biopsy specimens identified lamina propria T cells as target cells undergoing apoptosis. CONCLUSIONS: These in vivo observations support the notion that colonic uptake of (99m)Tc-annexin V correlates with clinical benefit of anti-TNF treatment and might be predictive of therapeutic success.
Authors: Y Ogura; S M Krams; O M Martinez; S Kopiwoda; J P Higgins; C O Esquivel; H W Strauss; J F Tait; F G Blankenberg Journal: Radiology Date: 2000-03 Impact factor: 11.105
Authors: F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; H W Strauss Journal: J Nucl Med Date: 1999-01 Impact factor: 10.057
Authors: L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391
Authors: Chong Shen; Philippe Maerten; Karel Geboes; Gert Van Assche; Paul Rutgeerts; Jan L Ceuppens Journal: Clin Immunol Date: 2005-06 Impact factor: 3.969
Authors: C Shen; G V Assche; S Colpaert; P Maerten; K Geboes; P Rutgeerts; J L Ceuppens Journal: Aliment Pharmacol Ther Date: 2005-02-01 Impact factor: 8.171
Authors: Roelof J Bennink; Jörg Hamann; Kora de Bruin; Fiebo J W ten Kate; Sander J H van Deventer; Anje A te Velde Journal: J Nucl Med Date: 2005-03 Impact factor: 10.057
Authors: Raja Atreya; Helmut Neumann; Clemens Neufert; Maximilian J Waldner; Ulrike Billmeier; Yurdagül Zopf; Marcus Willma; Christine App; Tino Münster; Hermann Kessler; Stefanie Maas; Bernd Gebhardt; Ralph Heimke-Brinck; Eva Reuter; Frank Dörje; Tilman T Rau; Wolfgang Uter; Thomas D Wang; Ralf Kiesslich; Michael Vieth; Ewald Hannappel; Markus F Neurath Journal: Nat Med Date: 2014-02-23 Impact factor: 53.440
Authors: Arunan S Vamadevan; Masayuki Fukata; Elizabeth T Arnold; Lisa S Thomas; David Hsu; Maria T Abreu Journal: Innate Immun Date: 2009-08-26 Impact factor: 2.680